Viloxazine (Qelbree) and Bupropion Co-Prescribing
Qelbree (viloxazine extended-release) and bupropion can generally be prescribed together because no contraindication for this specific combination is listed in the Qelbree prescribing information. [1] The primary interaction considerations involve Qelbree’s effects on CYP1A2 and Qelbree exposure changes related to CYP2D6 status rather than a direct listed prohibition with bupropion. [1]
Contraindications and Direct “Do Not Combine” Restrictions
Qelbree is contraindicated with monoamine oxidase inhibitors (MAOIs) and is contraindicated with concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range. [1] Bupropion is not listed as a contraindicated concomitant medication in the Qelbree prescribing information. [1]
Metabolism Pathways Relevant to Bupropion
Viloxazine exposure is higher in CYP2D6 poor metabolizers compared with extensive metabolizers (Cmax 21% higher and AUC0–24 26% higher at steady state). [1] Viloxazine is metabolized by CYP2D6 (among other pathways), so CYP2D6 inhibition can be expected to increase viloxazine exposure in a similar direction to CYP2D6 poor metabolizer physiology. [1] Bupropion is a CYP2D6 inhibitor, which increases the likelihood of increased exposure to viloxazine, even though a specific bupropion–viloxazine interaction study result is not provided in the Qelbree label. [1]
Interaction Mechanisms Driving Clinical Monitoring
Qelbree is a reversible inhibitor of CYP1A2, CYP2B6, CYP2D6, and CYP3A4/5 in vitro, so concomitant use with drugs that are sensitive CYP1A2 substrates requires avoidance when those substrates have narrow therapeutic windows. [1] Qelbree’s CYP inhibition profile supports monitoring for adverse effects from other concomitant CYP-metabolized therapies when clinically relevant. [1]
Practical Co-Prescribing Approach
If bupropion is co-prescribed with Qelbree, monitoring for Qelbree-related adverse effects is recommended due to the possibility of increased viloxazine exposure from CYP2D6 inhibition. [1] Vital sign monitoring should be performed during Qelbree titration and periodically thereafter because Qelbree can increase blood pressure and heart rate. [1] If problematic adverse effects occur after initiation or dose increases, dose adjustment of Qelbree should be considered by the prescriber based on clinical tolerance. [1]
Initiation and Safety Timing Considerations
Qelbree should not be started in patients receiving MAOIs or within 14 days after discontinuing an MAOI. [1] Dose titration for Qelbree is performed in increments over time, which provides an opportunity to detect adverse effects early when combined with additional CNS-active agents such as bupropion. [1]
Common Pitfalls to Avoid
Avoiding CYP1A2 narrow-therapeutic-range substrates is a key pitfall, as Qelbree contraindicates concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range. [1] Overlooking CYP2D6-related exposure increases in CYP2D6 poor metabolizers is another pitfall, because a similar exposure direction may occur with CYP2D6 inhibition. [1]
Adverse-Effect Surveillance Priorities
Blood pressure and heart rate should be assessed prior to Qelbree initiation, after increases in dosage, and periodically during therapy. [1] Monitoring for suicidality and for activation of mania or hypomania is part of the Qelbree safety surveillance strategy during ongoing treatment. [1]
Bottom-line Clinical Answer
Co-prescribing bupropion with Qelbree is not contraindicated in the Qelbree prescribing information. [1] The combination should be managed with attention to possible increased viloxazine exposure from CYP2D6 inhibition and with standard Qelbree safety monitoring, especially cardiovascular parameters. [1]